PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced on April 8, 2026, that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting (AGM 2026) with a large majority. The meeting, held at the Chollerhalle in Zug, saw representation of 26,780,855 shares with voting rights, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for the same term. The shareholders also approved the re-election of Statutory Auditors and the Independent Proxy, as well as the maximum aggregate compensation for the Board of Directors and Executive Committee.
Discharge was granted to all Board and Executive Committee members for their activities in the financial year 2025. The shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for fiscal year 2025, along with the Remuneration Report 2025 in a separate consultative vote. The minutes of AGM 2026 will be available within 15 days on the Company’s website.
The strong shareholder support underscores confidence in PolyPeptide’s strategic direction and governance. As a specialized CDMO for peptide-based APIs, PolyPeptide serves a fast-growing market, particularly in metabolic diseases including GLP-1, with six GMP-certified facilities in Europe, the U.S., and India. The next annual General Meeting is scheduled for April 7, 2027.
